Calcitonin gene-related peptide monoclonal antibody: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
VisualWikitext
m (→‎Drugs: links)
m (Text replacement - "|journal=" to " | journal = ")
 
(33 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{stub}}
{{stub}}
'''Calcitonin gene-related peptide monoclonal antibodies''' (mAbs) or '''CGRP mAbs''' are a new type of preventative [[migraine]] treatment.<ref name="migrainetrust">{{Cite web|url=https://migrainetrust.org/live-with-migraine/healthcare/treatments/calcitonin-gene-related-peptide-monoclonal-antibodies/|title=Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies|website=The Migraine Trust|language=en-US|access-date=2021-10-12}}</ref><ref name="drugscom" /> CGRP mAbs block the release of calcitonin gene-related peptide, a neurotransmitter known to cause migraines.
'''Calcitonin gene-related peptide monoclonal antibodies''' (mAbs) or '''CGRP mAbs''' are a new type of preventative [[migraine]] treatment.<ref name="migrainetrust">{{Cite web | url = https://migrainetrust.org/live-with-migraine/healthcare/treatments/calcitonin-gene-related-peptide-monoclonal-antibodies/ | title = Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies | website = The Migraine Trust|language=en-US | access-date = 2021-10-12}}</ref><ref name="drugscom" /> CGRP mAbs block the release of calcitonin gene-related peptide, a neurotransmitter known to cause migraines.


Unlike known the small molecule CGRP antagonists known as [[:Category:Gepants|gepants]], CGRP mAbs are used for preventation rather than treatment of an existing migraine.<ref name="drugscom">{{Cite web|url=https://www.drugs.com/medical-answers/new-drugs-treatment-prevention-migraine-3515053/|title=What are the new drugs for the treatment of migraines?|website=Drugs.com|language=en|access-date=2021-10-12}}</ref><ref name="gepants">{{Cite journal|last=Negro|first=Andrea|author-link=|last2=Martelletti|first2=Paolo|author-link2=|last3=|first3=|author-link3=|last4=|first4=|author-link4=|last5=|first5=|author-link5=|last6=|first6=|author-link6=|last7=|first7=|last8=|first8=|date=Jun 2019|title=Gepants for the treatment of migraine|url=https://pubmed.ncbi.nlm.nih.gov/31081399/|journal=Expert Opinion on Investigational Drugs|volume=28|issue=6|pages=555–567|doi=10.1080/13543784.2019.1618830|issn=1744-7658|pmc=|pmid=31081399|access-date=|quote=|via=}}</ref>
Unlike known the small molecule CGRP antagonists known as [[:Category:Gepants|gepants]], CGRP mAbs are used for preventation rather than treatment of an existing migraine.<ref name="drugscom">{{Cite web | url = https://www.drugs.com/medical-answers/new-drugs-treatment-prevention-migraine-3515053/ | title = What are the new drugs for the treatment of migraines? | website = Drugs.com|language=en | access-date = 2021-10-12}}</ref><ref name="gepants">{{Cite journal | last = Negro | first = Andrea | author-link = | last2 = Martelletti | first2 = Paolo | author-link2 = | date = Jun 2019 | title = Gepants for the treatment of migraine | url =https://pubmed.ncbi.nlm.nih.gov/31081399/ | journal = Expert Opinion on Investigational Drugs | volume = 28 | issue = 6 | pages = 555–567|doi=10.1080/13543784.2019.1618830|issn=1744-7658|pmc=|pmid=31081399|access-date=|quote=|via=}}</ref>


==Drugs==
==Drugs==
Line 12: Line 12:


== Uses ==
== Uses ==
A small retrospective chart review by Kang and Govindarajan (2020) found that CGRP mAbs also significantly decreased peripheral nerve [[pain]] in patients who also had migraines.<ref>{{Cite journal|last=Kang|first=Seung Ah|last2=Govindarajan|first2=Raghav|date=2021|title=Anti-calcitonin gene–related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache|url=https://onlinelibrary.wiley.com/doi/abs/10.1002/mus.27153|journal=Muscle & Nerve|language=en|volume=63|issue=4|pages=563–567|doi=10.1002/mus.27153|issn=1097-4598}}</ref>
A small retrospective chart review by Kang and Govindarajan (2020) found that CGRP mAbs also significantly decreased peripheral nerve [[pain]] in patients who also had migraines.<ref>{{Cite journal | last = Kang | first = Seung Ah | last2 = Govindarajan | first2 = Raghav | date = 2021 | title=Anti-calcitonin gene–related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache | url =https://onlinelibrary.wiley.com/doi/abs/10.1002/mus.27153 | journal = Muscle & Nerve|language=en | volume = 63 | issue = 4 | pages = 563–567|doi=10.1002/mus.27153|issn=1097-4598}}</ref>


==News and articles ==
==News and articles ==
Line 32: Line 32:
[[Category:Antibodies]]
[[Category:Antibodies]]
[[Category:Potential treatments]]
[[Category:Potential treatments]]
[[Category:Antimigraine agents]]

Latest revision as of 16:57, April 3, 2023

Calcitonin gene-related peptide monoclonal antibodies (mAbs) or CGRP mAbs are a new type of preventative migraine treatment.[1][2] CGRP mAbs block the release of calcitonin gene-related peptide, a neurotransmitter known to cause migraines.

Unlike known the small molecule CGRP antagonists known as gepants, CGRP mAbs are used for preventation rather than treatment of an existing migraine.[2][3]

Drugs[edit | edit source]

Currently FDA-licensed CGRP mAbs are:

Uses[edit | edit source]

A small retrospective chart review by Kang and Govindarajan (2020) found that CGRP mAbs also significantly decreased peripheral nerve pain in patients who also had migraines.[4]

News and articles[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ "Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies". The Migraine Trust. Retrieved October 12, 2021.
  2. ↑ 2.0 2.1 2.2 "What are the new drugs for the treatment of migraines?". Drugs.com. Retrieved October 12, 2021.
  3. ↑ Negro, Andrea; Martelletti, Paolo (June 2019). "Gepants for the treatment of migraine". Expert Opinion on Investigational Drugs. 28 (6): 555–567. doi:10.1080/13543784.2019.1618830. ISSN 1744-7658. PMID 31081399.
  4. ↑ Kang, Seung Ah; Govindarajan, Raghav (2021). "Anti-calcitonin gene–related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache". Muscle & Nerve. 63 (4): 563–567. doi:10.1002/mus.27153. ISSN 1097-4598.

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

antagonist A chemical that reduces or helps block the activity of another chemical in the body. For example, most antihistamines are H1 antagonists because they block the H1 histamine receptor, which helps relieve allergy symptoms. The opposite of an agonist.

Retrieved from "https://me-pedia.org/w/index.php?title=Calcitonin_gene-related_peptide_monoclonal_antibody&oldid=240587"